Next 10 |
home / stock / roiv / roiv articles
Tuesday, Roivant Sciences (NASDAQ:ROIV) and Priovant Therapeutics announced results from the Phase 2 study (NEPTUNE) evaluating brepociti...
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future g...
BASEL, Switzerland and LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today reported its financial results for the...
Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topic...
Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of ba...
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. Shares of FedEx Corporation (NYSE: F...
BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) announced today the completion of the previo...
Roivant Sciences Ltd (NASDAQ: ROIV) and Priovant's Phase 2 study of oral brepocitinib in moderate to severe active lupus did not...
BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced the appointment of Mayukh Su...
News, Short Squeeze, Breakout and More Instantly...
Roivant Sciences Ltd. Company Name:
ROIV Stock Symbol:
NASDAQ Market:
2024-04-24 07:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-14 09:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-02 17:15:03 ET Goldman Sachs analyst issues BUY recommendation for ROIV on April 2, 2024 03:55PM ET. The previous analyst recommendation was Buy. ROIV was trading at $10.92 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...